Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease

Estuary launched with committed seed and Series A financing. GV participated in the Series A led by RA Capital Management and had co-led the seed financing with 4BIO Capital. Proceeds support kidney gene-therapy development.